News Image

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

Provided By GlobeNewswire

Last update: Jun 2, 2025

PHILADELPHIA and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today presents clinical data in three clinical poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. BriaCell has featured robust survival and clinical benefit data from its Bria-IMT Phase 2 clinical study, clinical progress data from its ongoing pivotal Bria-IMT Phase 3 study (ClinicalTrials.gov identifier: NCT06072612), and Phase 1/2 study of Bria-OTS (ClinicalTrials.gov identifier: NCT06471673) in metastatic breast cancer.

Read more at globenewswire.com

BRIACELL THERAPEUTICS CORP

NASDAQ:BCTX (7/30/2025, 8:00:01 PM)

Premarket: 0.8087 +0.01 (+0.71%)

0.803

0 (-0.27%)


BRIACELL THERAPEUTICS -CW27

NASDAQ:BCTXW (7/30/2025, 8:00:01 PM)

Premarket: 0.045 0 (-7.02%)

0.0484

0 (-2.81%)


BRIACELL THERAPEUTICS - 30

NASDAQ:BCTXZ (7/29/2025, 8:00:00 PM)

0.3399

+0.03 (+9.68%)



Find more stocks in the Stock Screener

Follow ChartMill for more